Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Am Pharm Assoc (2003) ; 43(3): 375-8, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12836787

RESUMO

OBJECTIVE: Identify, during the period of criminal anthrax exposures in October 2001, changes in utilization of ciprofloxacin and geographic patterns of any identified variations. DESIGN: Observational. SETTING: United States. PATIENTS: Individuals making prescription claims through a pharmacy benefits management company. INTERVENTIONS: Analysis of AdvancePCS pharmacy claims database. MAIN OUTCOME MEASURES: Percentage change in ciprofloxacin utilization for 2000 and 2001 and, by locale, for September and October 2001. RESULTS: Utilization of ciprofloxacin tablets was significantly lower in calendar year 2001 than in calendar year 2000 (median decline, 10.3%) for all months except October, when utilization of ciprofloxacin increased 9.8%. During the period of anthrax exposures (October 2001 versus September 2001), affected geographic areas, including New York (an increase of 62.5%), some other Mid-Atlantic states, and Florida (28.5%), had some of the highest percentage increases in the rate of ciprofloxacin utilization. CONCLUSION: Many Americans actively sought prophylaxis with ciprofloxacin during the course of the October 2001 anthrax attack and that utilization was higher in, but not limited to, locales with publicized cases of disease. Pharmacists, clinicians, and public health officials should note that such behavior may be expected in the event of a similar attack and should be familiar with current recommendations for the assessment and management of anthrax exposure.


Assuntos
Antraz/tratamento farmacológico , Anti-Infecciosos/uso terapêutico , Ciprofloxacina/uso terapêutico , Revisão de Uso de Medicamentos/tendências , Análise de Variância , Antraz/epidemiologia , Antraz/prevenção & controle , Bioterrorismo , Centers for Disease Control and Prevention, U.S./normas , Crime , Bases de Dados Factuais , Exposição Ambiental/efeitos adversos , Humanos , Estados Unidos , United States Food and Drug Administration/normas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA